Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)

<Previous Article In Volume
Next Article In Volume>

Development and Evaluation of Losartan Potassium Nanoparticles: A Comprehensive Study

Authors
Sailaja Gunnam1, *, Goday Swapna2, Monika Nijhawan1, Rajeswari Aleti1, T. Lakshmi Sowmya1, Shruthi Kanna1, B. Naga Swathi2, Prodduturi Vamsi Krishna2, Md. Bazlur Rahman2
1Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Nizampet, Bachupally, Hyderabad, Telangana, India
2Department of Analysis, Nirmala College of Pharmacy, Atmakur, Mangalagiri, Guntur, Andhra Pradesh, India
*Corresponding author. Email: sailugunnam@gmail.com
Corresponding Author
Sailaja Gunnam
Available Online 13 August 2025.
DOI
10.2991/978-94-6463-813-4_2How to use a DOI?
Keywords
Losartan; Angiotensin receptor blocker (ARB); FTIR
Abstract

Losartan, an angiotensin receptor blocker utilized in treating hypertension, exhibits a biological half-life of around 1.5 to 2 h, necessitating frequent administration. To reduce the frequency of dose, attain targeting effect, and improve patient compliance. To achieve a sustained release profile, Losartan potassium nanoparticles (LNPs) were developed using polymers such as Ethyl Cellulose, Eudragit RS 100, and Eudragit RL 100 in varying ratios. Physicochemical characterization of prepared nanoparticles included FTIR, particle size, surface morphology, zeta potential and percentage yield. The FTIR study revealed there is no drug interaction. Drug release studies were conducted under physiological conditions to determine the release kinetics. Optimized formulation (LNP6) has shown sustained drug release of about 12 h. SEM results confirmed that formulation (LNP6) had nanoparticles within the nanometer size range, and the zeta potential results indicated stability. The formulation and evaluation of LNP represent a promising strategy to overcome the limitations associated with conventional dosage forms, thereby enhancing the therapeutic potential of this vital antihypertensive medication.

Copyright
© 2025 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
Series
Advances in Health Sciences Research
Publication Date
13 August 2025
ISBN
978-94-6463-813-4
ISSN
2468-5739
DOI
10.2991/978-94-6463-813-4_2How to use a DOI?
Copyright
© 2025 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Sailaja Gunnam
AU  - Goday Swapna
AU  - Monika Nijhawan
AU  - Rajeswari Aleti
AU  - T. Lakshmi Sowmya
AU  - Shruthi Kanna
AU  - B. Naga Swathi
AU  - Prodduturi Vamsi Krishna
AU  - Md. Bazlur Rahman
PY  - 2025
DA  - 2025/08/13
TI  - Development and Evaluation of Losartan Potassium Nanoparticles: A Comprehensive Study
BT  - Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
PB  - Atlantis Press
SP  - 3
EP  - 13
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-813-4_2
DO  - 10.2991/978-94-6463-813-4_2
ID  - Gunnam2025
ER  -